FDA clears NuVasive’s updated spine implant system for scoliosis

The redesigned MAGEC system introduces a new rod size and new components that facilitate the treatment of early-onset scoliosis.

NuVasive scored FDA clearance for its spinal implant system for the treatment of early-onset scoliosis.

Picked up in Nuvasive’s $380 million acquisition of Ellipse Technologies, the MAGnetic External Control (MAGEC) Spinal Bracing and Distraction System is FDA-cleared for early-onset and idiopathic scoliosis. The new clearance is for the redesigned MAGEC system with the RELINE Small Stature system.

MAGEC uses magnetic technology with adjustable growing rods to treat scoliosis in a less invasive manner. Follow-up surgeries to change the rods’ length are not required—instead, an external remote controller is used to adjust the rods. The RELINE system is a comprehensive pediatric deformity fixation platform.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The new design includes components that make the system easier for a surgeon to use, and to make surgical outcomes more reproducible, the company said in a statement. The company is also introducing a new 5-millimeter rod. The RELINE system is the only small-stature system compatible with this rod size.

"As a low-profile pediatric fixation system, RELINE Small Stature is the first-of-its-kind system to offer competitively-sized pediatric implants that accept up to a 5.0mm rod," said Matt Link, executive vice president of strategy, technology and corporate development at NuVasive, in the statement. "The clearance for our redesigned MAGEC system with RELINE Small Stature highlights our speed to market and our further commitment to bringing procedural solutions that transform care to the pediatric deformity market."

In March, the FDA cleared Nuvasive’s CoRoent Small Interbody System for the fusion of vertebral bodies—the main portion of each vertebra—for multiple levels in the cervical spine. It is used for the treatment of cervical disc degeneration, and is the first cervical cage system to be approved for the treatment of up to four adjacent levels of the spine.


Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.